Prognostic Value of Response Evaluation Using PSMA PET/CT in Patients with Metastatic Prostate Cancer (RECIP 1.0): A...

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Prostate-specific membrane antigen (PSMA) PET/CT is crucial for evaluating treatment response in metastatic castration-resistant prostate cancer (mCRPC).
• Traditional criteria like PERCIST 1.0 have limitations.
• The RECIP 1.0 system was developed to improve response assessment using PSMA PET/CT.

Purpose of the Study:

• To systematically review and meta-analyze the prognostic performance of RECIP 1.0.
• To evaluate RECIP 1.0's ability to predict treatment outcomes in mCRPC patients.
• To compare RECIP 1.0 with other criteria like PSMA PET Progression Criteria (PPP).

Main Methods:

• Systematic literature search of PubMed, EMBASE, and Web of Science databases up to March 2024.
• Inclusion of studies assessing therapeutic response in mCRPC patients using PSMA PET/CT and RECIP 1.0 criteria.
• Pooled analysis of hazard ratios for mortality and concordance indices (c-index); secondary head-to-head comparison with PPP.

Main Results:

• Eight studies (516 patients) met eligibility criteria; six were included in quantitative analysis.
• RECIP 1.0 significantly differentiated mortality risk between disease progression and non-progression (HR: 3.48).
• Pooled c-index for RECIP 1.0 was 0.68; a non-significant trend favored RECIP 1.0 over PPP in head-to-head comparisons.

Conclusions:

• RECIP 1.0 demonstrates robust prognostic value for assessing treatment outcomes in mCRPC.
• The RECIP 1.0 criteria enhance the evaluation of therapeutic response in prostate cancer.
• Further validation supports the clinical utility of RECIP 1.0 in mCRPC management.